Many elites gathered to share the trend of biomedical innovation

Liu Wenyi, managing partner of Xingze Capital, the organizer, said in his opening speech that 2023 is the outbreak year of China's innovative drug assets offshore transactions, the number of transactions is equal to the sum of the past three years,

and enterprises incubated by Xingze Capital have grown into the main contributor to offshore transactions. New technology has brought new changes, and China's biotechnology has completed the process of 40 years in the United States in ten years, and is now moving forward vigorously with an unstoppable trend.

Bi Jingquan, a member of the Standing Committee of the CPPCC National Committee, deputy director of the Economic Committee and chairman of the China Center for International Economic Exchanges, said that since the 18th National Congress of the CPC,

China's biopharmaceutical has achieved a transformation from generics to innovative drugs and a combination of imitation and creation. Relevant departments are actively studying and exploring relevant policies and measures to support the development of innovative drugs from all aspects of the biomedical life cycle.

Many local governments have formulated policies and measures to support the development of the innovative drug industry. With the joint efforts of relevant departments, problems such as low price of innovative drugs, difficulty in entering hospitals, and difficulty in financing have begun to ease.

Zhan Qimin, academician of the Chinese Academy of Engineering, Professor Boya of Peking University, dean of the International Cancer Research Institute of Peking University and dean of the School of Medicine of Soochow University,

said in his speech that China's biomedical field faces problems such as independent innovation ability to be further improved, the small scale of the biotechnology industry, and urgent breakthroughs in key technologies of industrialization.

It is necessary to develop cutting-edge biotechnology, and continue to make efforts in the fields of bioomics technology, innovative drugs, vaccines and antibodies, modern medical devices, and big data and smart medicine.

During the round table forum, leaders of competent departments and experts in academic fields conducted wonderful discussions on issues related to regulation and enterprises. Li Jiange, executive director of CWM50 and chairman of Sun Yefang Economic Science Foundation,

pointed out that whether innovative drugs can develop and grow depends on the payer in the final analysis. Because China has built a social security system, the medical payment ability of urban workers, urban and rural residents and other people has been greatly improved,

and the development of innovative drugs has built a growth track; He Ruyi, chief medical officer of Rongchang Biology, chief scientist of SDI Life Sciences, and chief scientist of the former Drug Review center of the State Food and Drug Administration,

said that supervision and enterprises are not opposite sides, research and development of innovative drugs, improve the health of the people, both sides have the same goal, so communication must be strengthened and accelerated.

It can promote the joint improvement of supervision and enterprises through revolving door talent training; Liu Guoen, dean of the Global Health Development Institute of Peking University,

distinguished Professor of Changjiang Scholars of the National Development Institute of Peking University, and member of the Faculty of the Chinese Academy of Medical Sciences, pointed out that the primary purpose of China's medical insurance is to ensure basic and full coverage,

and in the case of limited affordability of universal medical insurance, the future new drug market can expand from universal medical insurance to non-universal medical insurance commercial market.

After experts demonstrated the development status and innovation prospects of the biomedicine industry, executives of industry investment institutions and business leaders shared the investment strategy and development trend of China's biomedicine industry.

Strong Jing, managing partner of Xingze Capital, believes that in today's era, only execution can create value. Investment innovation is not easy, but Xingze Capital has been insisting on doing difficult and right things. Over the past decade, any investment based on arbitrage has turned out to be a value destroyer.

Investment institutions should be based on the long-term layout of the stage of industrial development, rather than catering to the hot spots of the capital market. In the next ten years, we must embrace the arrival of the great era of navigation at sea.

Tang Renhong, executive director of Simcere Pharmaceutical and CEO of Simcere Re Ming, said that the commercial value of innovative drugs is reflected in whether they are more effective and differentiated. For potential clinical premarket products,

more attention needs to be paid to whether they have a competitive advantage in the treatment of diseases, such as whether the effectiveness exceeds the existing drug therapies, whether the safety has been improved, and whether better efficacy and compliance can be achieved through different pathways.